Wim Souverijns Sells 10,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Wim Souverijns sold 10,000 shares of the business’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $29.92, for a total value of $299,200.00. Following the completion of the transaction, the insider directly owned 45,111 shares of the company’s stock, valued at approximately $1,349,721.12. This trade represents a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Pharvaris Trading Up 1.7%

Pharvaris stock opened at $29.45 on Thursday. The firm has a market capitalization of $1.93 billion, a P/E ratio of -9.26 and a beta of -2.34. The stock has a fifty day moving average price of $28.32 and a 200 day moving average price of $26.73. Pharvaris N.V. has a 52 week low of $15.46 and a 52 week high of $33.33.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. As a group, equities analysts predict that Pharvaris N.V. will post -3.25 EPS for the current year.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently added to or reduced their stakes in the company. Stempoint Capital LP grew its position in Pharvaris by 48.4% during the first quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock valued at $2,447,000 after acquiring an additional 28,248 shares during the period. ADAR1 Capital Management LLC grew its position in Pharvaris by 23.4% during the first quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock valued at $2,981,000 after acquiring an additional 20,000 shares during the period. Amundi grew its position in Pharvaris by 12.0% during the first quarter. Amundi now owns 30,952 shares of the company’s stock valued at $874,000 after acquiring an additional 3,312 shares during the period. Rock Springs Capital Management LP grew its position in Pharvaris by 3.6% during the first quarter. Rock Springs Capital Management LP now owns 645,533 shares of the company’s stock valued at $18,236,000 after acquiring an additional 22,131 shares during the period. Finally, SummitTX Capital L.P. grew its position in Pharvaris by 27.7% during the first quarter. SummitTX Capital L.P. now owns 29,184 shares of the company’s stock valued at $824,000 after acquiring an additional 6,325 shares during the period.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright raised earnings estimates across multiple periods for Pharvaris, including FY2026 through FY2030, while reiterating a Buy rating and a $60 price target, signaling improved longer-term expectations for the clinical-stage biotech.
• Neutral Sentiment: Pharvaris recently reported a smaller-than-expected quarterly loss, posting EPS of ($0.70) versus the consensus estimate of ($0.82), which supports sentiment but still reflects ongoing losses.
• Negative Sentiment: CEO Berndt Modig sold 2,292 shares at an average price of $29.22, trimming his position slightly and adding to investor focus on insider activity.
• Negative Sentiment: Director Robert Glassman sold 10,000 shares, and insider Wim Souverijns also sold 10,000 shares, which may weigh on sentiment because investors often view insider selling as a sign of reduced confidence. Robert Glassman SEC filing Wim Souverijns SEC filing

Analysts Set New Price Targets

Several research firms recently commented on PHVS. Citizens Jmp dropped their target price on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Wall Street Zen upgraded Pharvaris from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Wolfe Research began coverage on Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.